Journal Article

Nucleoside Inhibitors of Zika Virus

Luděk Eyer, Radim Nencka, Ivana Huvarová, Martin Palus, Maria Joao Alves, Ernest A. Gould, Erik De Clercq and Daniel Růžek

in The Journal of Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 214, issue 5, pages 707-711
Published in print September 2016 | ISSN: 0022-1899
Published online May 2016 | e-ISSN: 1537-6613 | DOI: https://dx.doi.org/10.1093/infdis/jiw226
Nucleoside Inhibitors of Zika Virus

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

There is growing evidence that Zika virus (ZIKV) can cause devastating infant brain defects and other neurological disorders in humans. However, no specific antiviral therapy is available at present. We tested a series of 2′-C- or 2′-O-methyl–substituted nucleosides, 2′-C-fluoro-2′-C-methyl–substituted nucleosides, 3′-O-methyl–substituted nucleosides, 3′-deoxynucleosides, derivatives with 4′-C-azido substitution, heterobase-modified nucleosides, and neplanocins for their ability to inhibit ZIKV replication in cell culture. Antiviral activity was identified when 2′-C–methylated nucleosides were tested, suggesting that these compounds might represent promising lead candidates for further development of specific antivirals against ZIKV.

Keywords: Zika virus; flavivirus; nucleoside analogue; antiviral; therapy

Journal Article.  2650 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.